About Q-Sera
Q-Sera is a Healthcare company based in Melbourne (Australia) founded in 2012. Technology to enable blood clotting. Q-Sera has raised $900 thousand across 1 funding round from investors including Medical Research Commercialisation Fund and Uniseed. Its chief executive, as recorded, is Michael Grant. Q-Sera offers products and services including RAPClot Rapid Serum Tubes and Recombinant Ecarin. Its focus areas include Diversified Diagnostics. Its legal entity is Q-Sera Pty Ltd.
Company details
Q-Sera is commercializing a potent prothrombin activation factor discovered in the venom of the Australian Taipan for use as a clotting reagent in diagnostic and other clinical and research settings. The factor is coated on to the inner surface of blood collection tubes to ensure efficient clotting of collected blood samples, even in patients who are on anti-coagulation medication such as Warfarin.
- Headquarters Melbourne, Australia
- SectorsHealthcare
- Phone•••• ••••
- Website q-sera.com
- Legal Name Q-Sera Pty Ltd
- Total Equity Funding$900K (USD)
in 1 rounds
- Latest Funding Round$900K (USD), Seed
Jun 2012
- Investors
Products & Services of Q-Sera
Q-Sera offers a comprehensive portfolio of products and services, including RAPClot Rapid Serum Tubes and Recombinant Ecarin.
Tubes that rapidly produce high-quality serum for accurate biochemical analysis.
Protein for clotting blood in medical devices and diagnostics applications.
Funding Insights of Q-Sera
Q-Sera has successfully raised a total of $900K through 1 strategic funding round. The most recent funding activity was a Seed round of $900 thousand completed in June 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $900,000
- Total Rounds 1
- Last Round Seed — $900,000
- First Round $900,000
(Jun 2012)
- Investors Count 2
All 1 funding rounds of Q-Sera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2012 | $900,000 | Seed | – | – |
2 investors in total: 2 institutional.
Investors in Q-Sera
Q-Sera has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Medical Research Commercialisation Fund and Uniseed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed & Early stage Life-Sciences focused VC Firm investing primarily in Australia | mrcf.com.au | Melbourne, Australia | ||
Seed-stage investments are directed toward Australian companies. | uniseed.com | Brisbane, Australia |
Investor details for Q-Sera
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Q-Sera
1 people are tracked at Q-Sera (1 in leadership).
| Name | Role | Group |
|---|---|---|
Michael Grant | CEO | Leadership |
Complete people profiles for Q-Sera
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Q-Sera
2 dated milestones of Q-Sera, from founding to its latest funding, stage changes and deals.
- Founded Q-Sera is founded.
- Funding First funding round of $900K.
Web traffic of Q-Sera
The website of Q-Sera (q-sera.com) receives about 6.3K visits a month.
- Monthly visits6.3K
▲ 192.4% vs previous month
Websites whose visitors overlap most with Q-Sera. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| palsonsderma.com | 100% | 11.3K | #1,960,259 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Q-Sera
Complete news archive for Q-Sera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Q-Sera
Q-Sera was founded in 2012.
Q-Sera is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.
Michael Grant is the CEO of Q-Sera, as recorded in our data.
Q-Sera is a funded company, having raised a total of $900K across 1 funding round to date. The company's 1st funding round was a Seed of $900K, raised on Jun 2012.
Q-Sera is commercializing a potent prothrombin activation factor discovered in the venom of the Australian Taipan for use as a clotting reagent in diagnostic and other clinical and research settings. The factor is coated on to the inner surface of blood collection tubes to ensure efficient clotting of collected blood samples, even in patients who are on anti-coagulation medication such as Warfarin.
Q-Sera offers RAPClot Rapid Serum Tubes and Recombinant Ecarin.
Q-Sera has 2 investors. Key investors include Medical Research Commercialisation Fund, and Uniseed.
Q-Sera operates through Q-Sera Pty Ltd.